Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
Tankyrase Inhibitor OM153 Exhibits Anti-Fibrotic Effects in a Scar-in-a-Jar Pulmonary Fibrosis Model
May 17, 2025
Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic and fatal lung disease with limited
treatment options. Fibroblast activation and ECM deposition is pivotal in development of IPF, thus
inhibiting fibrogenesis and ECM deposition is crucial for anti-fibrotic approaches to treat IPF.
This study aims to prove that tankyrase inhibition reduces fibrogenesis induced by a fibrotic cocktail (FC) in primary human lung fibroblasts derived from IPF patients and decreases extracellular matrix biomarkers nordicPRO-C3 TM and nordicPRO-C6TM.
Poster
Conclusion
These findings highlight the potential of tankyrase inhibiton as a therapeutic target for IPF and
support the use of the Scar–in-a-Jar model as an effective tool for IPF drug screening.
